Tilson-Mallett N, Santner S J, Feil P D, Santen R J
J Clin Endocrinol Metab. 1983 Dec;57(6):1125-8. doi: 10.1210/jcem-57-6-1125.
Human breast carcinomas contain aromatase, the enzyme necessary for the conversion of androgens to estrogens. If present in sufficient amounts, aromatase could catalyze the synthesis of estrogens from plasma steroid precursors and produce high breast cancer tissue concentrations. To determine the biological importance of tumor aromatase, we validated a specific and highly sensitive 3H-labeled water release assay for aromatase and used this to quantitate the amount of estrogen synthesized in vitro in breast tumors. As proof of assay validity, the [3H] water release assay detected 22.7 +/- 0.09 (+/- SEM) pmol/g . h estrogen formed vs. 24.7 pmol/g . h with the direct product isolation assay. Of 61 human breast tumors studied, 48 contained measurable aromatase activity, ranging from 5-70.5 pmol estrone formed/g . h. Three aromatase inhibitors (aminoglutethimide, testololactone, and 4-hydroxyandrostenedione) blocked this activity at concentrations similar to those affecting aromatase activity in other tissues. If biologically important, the estrogen formed locally from aromatase would be expected to stimulate production of the progesterone receptor. Under these circumstances, a positive correlation of progesterone receptor and local estrogen production should be found. In contrast, no significant correlation between aromatase activity and progesterone receptor level was observed (r = -0.27; P = NS). In addition, no correlation between estrogen receptor content and aromatase activity was detected. Finally, the amount of aromatase activity present in most tumors was insufficient to produce biologically meaningful saturation of estrogen receptors. These observations suggested that aromatase, while present in the majority of breast cancer tissues, may only be biologically important in those few tumors with very high aromatase activity.
人类乳腺癌中含有芳香化酶,这是一种将雄激素转化为雌激素所必需的酶。如果含量充足,芳香化酶可催化血浆类固醇前体合成雌激素,并在乳腺癌组织中产生高浓度雌激素。为了确定肿瘤芳香化酶的生物学重要性,我们验证了一种针对芳香化酶的特异性且高度灵敏的3H标记水释放测定法,并使用该方法对乳腺肿瘤体外合成的雌激素量进行定量。作为测定法有效性的证据,[3H]水释放测定法检测到形成的雌激素为22.7±0.09(±标准误)pmol/g·小时,而直接产物分离测定法检测到的为24.7 pmol/g·小时。在所研究的61例人类乳腺肿瘤中,48例含有可测量的芳香化酶活性,范围为形成雌酮5 - 70.5 pmol/g·小时。三种芳香化酶抑制剂(氨鲁米特、睾内酯和4 - 羟基雄烯二酮)在与影响其他组织中芳香化酶活性相似的浓度下阻断了该活性。如果具有生物学重要性,由芳香化酶在局部形成的雌激素预计会刺激孕激素受体的产生。在这种情况下,应发现孕激素受体与局部雌激素产生呈正相关。然而,未观察到芳香化酶活性与孕激素受体水平之间存在显著相关性(r = -0.27;P = 无显著性差异)。此外,未检测到雌激素受体含量与芳香化酶活性之间的相关性。最后,大多数肿瘤中存在的芳香化酶活性量不足以使雌激素受体产生具有生物学意义的饱和。这些观察结果表明,芳香化酶虽然存在于大多数乳腺癌组织中,但可能仅在少数具有非常高芳香化酶活性的肿瘤中具有生物学重要性。